NCT02176187终止3 期
A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 3
- 主要终点
- Percentage of dose in the whole lung
研究概览
简要总结
Study to compare the effect of 'natural' as opposed to 'optimal' technique on the percentage of the dose received from the Respimat® inhaler and metered dose inhaler
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients must have a diagnosis of COPD and must meet the following spirometric criteria:
- •Patients must have relatively stable, mild to severe airway obstruction with an forced expiratory volulme in one second (FEV1) ≤70% of predicted normal and FEV1 ≤70% of forced vital capacity (FVC). Predicted normal values calculated according to evolutionary conserved chromosome segments (ECCS)
- •Patients who have frequent exacerbations which could be expected to interfere with the patient's ability to participate in the study should be excluded
- •Male or non-pregnant/non-lactating female patients aged ≥18 years
- •Patients must demonstrate poor MDI technique prior to the start of the study. Presence of any of the following will be considered poor technique:
- •Failure to co-ordinate "firing" of an MDI with inhalation
- •Too fast an inhalation rate (> 30 litres/minute (L/min))
- •Presence of "Cold Freon" effect (MDI spray hitting the back of the throat that caused the patient to stop inhaling)
- •All patients must sign an informed consent form prior to participation in the study, i.e. prior to pre-study washout of their usual pulmonary medications
- •Current or ex-smokers with a smoking history of >10 pack years
排除标准
- •Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
- •Patients with clinically relevant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defines a disease listed as an exclusion criterion will be excluded
- •Patients with a recent history (i.e. six months or less) of myocardial infarction
- •Patients with any unstable or life-threatening cardiac arrhythmia or who have been hospitalised for heart failure within the past year
- •Patients who regularly use daytime oxygen therapy for more than 1 hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen
- •Patients with known active tuberculosis
- •Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma are allowed
- •Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
- •Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion 1
- •Patients with any upper respiratory infection in the past 14 days prior to the screening visit or during the baseline period
- •Patients who are currently in a pulmonary rehabilitation programme or who have completed a pulmonary rehabilitation programme in the six weeks prior to the screening visit
- •Patients with known hypersensitivity to β2-agonists, anticholinergic drugs or any excipients of the active or placebo Berodual®
- •Patients with known narrow-angle glaucoma
- •Patients who are being treated with antihistamines (H1 receptor antagonists)
- •Patients using oral corticosteroid medication at unstable doses (i.e. less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisolone per day or 20 mg every other day
- •Patients who are being treated with monamine oxidase inhibitors or tricyclic antidepressants
- •Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e. oral or injectable eg Depo-Provera or Noristerat contraceptives, intrauterine devices, diaphragm (plus spermicide) or subdermal implants eg: Norplant®)
- •Patients with, in the opinion of the investigator, a history of and/or active significant alcohol or drug abuse
- •Patients who have taken an investigational drug within four months or six half lives (whichever is the greater) prior to screening visit and/or the administration of radiolabelled dosage forms within the three months prior to the screening visit
- •Radiation exposure from clinical studies, including that from the present study and diagnostic X-rays but excluding background radiation, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last five years. No patient whose occupational exposure is monitored will participate in the study
- •Precautions: As with other anticholinergic drugs, Berodual® should be used with caution in patients with prostatic hyperplasia or bladder neck obstruction.
研究组 & 干预措施
natural technique, without instructions
Experimental
randomised sequence of Berodual® Respimat® and Berodual® MDI
干预措施: Berodual® Respimat® inhaler (Drug)
natural technique, without instructions
Experimental
randomised sequence of Berodual® Respimat® and Berodual® MDI
干预措施: Berodual® metered dose inhaler (Drug)
optimal technique, with instructions
Experimental
randomised sequence of Berodual® Respimat® and Berodual® MDI
干预措施: Berodual® Respimat® inhaler (Drug)
optimal technique, with instructions
Experimental
randomised sequence of Berodual® Respimat® and Berodual® MDI
干预措施: Berodual® metered dose inhaler (Drug)
结局指标
主要结局
Percentage of dose in the whole lung
时间窗: immediately after dosing
Deposition of aerosol via gamma scintigraphy
次要结局
- Percentage of dose in the peripheral lung zone deposition(immediately after dosing)
- Peripheral lung zone/central lung zone deposition ratio (lung penetration index)(immediately after dosing)
- Percentage of dose in oropharyngeal deposition(immediately after dosing)
- Percentage of dose in the central lung zone(immediately after dosing)
- Percentage of dose in the intermediate lung zone deposition(immediately after dosing)
研究者
相似试验
已完成
不适用
A Randomised, Multi-centre, Open-label Study to Compare the Safety and Efficacy Between Afatinib Monotherapy and Combination Therapy of Afatinib and HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR MutationsNeoplasmsKCT0005414Daejeon Korean Medicine Hospital of Daejeon University90
已完成
1 期
A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy VolunteersHealthyNCT05192395Daewoong Pharmaceutical Co. LTD.37
Unknown
4 期
Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or HypoxiaPulmonary Hypertension Secondary to Lung Disease and/or HypoxiaNCT01449253All India Institute of Medical Sciences, New Delhi60
尚未招募
3 期
An open randomised Comparative Study of 2 drug Vyoshadi Churna and Loha Bhasma in the Management of Pandu Roga with Special Reference to Iron Deficiency AnaemiaCTRI/2024/05/067409APMs Ayurved Mahavidyalaya
已完成
4 期
A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of AgeCystic FibrosisExocrine Pancreatic InsufficiencyNCT01100606Forest Laboratories15